Echocardiography, lung ultrasound, and cardiac magnetic resonance findings in COVID‐19: A systematic review

Barssoum, Kirolos; Victor, Varun; Salem, Ahmed; Kumar, Ashish; Mubasher, Mahmood; Hassib, Mohab; Magdi, Mohamed; Renjithlal, S.L. Mannumbeth; Abdelazeem, Mohamed; Shariff, Mariam; Idemudia, Osarenren; Ibrahim, Mounir; Mohamed, Amr; Thakkar, Samarthkumar; Patel, Harsh; Diab, Mohamed; Szeles, Andras; Ibrahim, Fadi; Jha, Roshan Kumar; Chowdhury, Medhat; Akula, Navya; Kalra, Ankur; Nanda, Navin C.

doi:10.1111/echo.15152

Cited by 14 publications

(20 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, its use to study pulmonary involvement in COVID-19 has increasingly risen. Recently, other systematic reviews have been published in an attempt to synthesise the available information and establish stronger evidence in this field [79] , [80] , [81] , [82] . However, these studies have only partially described lung ultrasound findings, focusing on the most common findings without exploring the frequency of occurrence of other phenomena.…”

Section: Discussionmentioning

confidence: 99%

Ultrasound findings of lung ultrasonography in COVID-19: A systematic review

Gil-Rodríguez

Rojas

Aranda-Laserna

et al. 2022

European Journal of Radiology

View full text Add to dashboard Cite

Purpose To identify the defining lung ultrasound (LUS) findings of COVID-19, and establish its association to the initial severity of the disease and prognostic outcomes. Method Systematic review was conducted according to the PRISMA guidelines. We queried PubMed, Embase, Web of Science, Cochrane Database and Scopus using the terms ((coronavirus) OR (covid-19) OR (sars AND cov AND 2) OR (2019-nCoV)) AND ((“lung ultrasound”) OR (LUS)), from 31st of December 2019 to 31st of January 2021. PCR-confirmed cases of SARS-CoV-2 infection, obtained from original studies with at least 10 participants 18 years old or older, were included. Risk of bias and applicability was evaluated with QUADAS-2. Results We found 1333 articles, from which 66 articles were included, with a pooled population of 4687 patients. The most examined findings were at least 3 B-lines, confluent B-lines, subpleural consolidation, pleural effusion and bilateral or unilateral distribution. B-lines, its confluent presentation and pleural abnormalities are the most frequent findings. LUS score was higher in intensive care unit (ICU) patients and emergency department (ED), and it was associated with a higher risk of developing unfavorable outcomes (death, ICU admission or need for mechanical ventilation). LUS findings and/or the LUS score had a good negative predictive value in the diagnosis of COVID-19 compared to RT-PCR. Conclusions The most frequent ultrasound findings of COVID-19 are B-lines and pleural abnormalities. High LUS score is associated with developing unfavorable outcomes. The inclusion of pleural effusion in the LUS score and the standardisation of the imaging protocol in COVID-19 LUS remains to be defined.

show abstract

Section: Discussionmentioning

confidence: 99%

Ultrasound findings of lung ultrasonography in COVID-19: A systematic review

Gil-Rodríguez

Rojas

Aranda-Laserna

et al. 2022

European Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…RVFWS is altered even in mild forms of COVID-19 and not necessarily in the presence of biomarkers indicating myocardial injury. However, RVFWS is more impaired in those with biochemical evidence of myocardial injury and is directly correlated with the disease severity [ 42 ]. Studies regarding the prognostic role of right ventricular fractional area change (RVFAC) have contradictory results, as this parameter is inconsistently associated with mortality rate [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, RVFWS is more impaired in those with biochemical evidence of myocardial injury and is directly correlated with the disease severity [ 42 ]. Studies regarding the prognostic role of right ventricular fractional area change (RVFAC) have contradictory results, as this parameter is inconsistently associated with mortality rate [ 42 ]. Right ventricular diameter was also correlated with mortality rates [ 40 , 43 ].…”

Section: Discussionmentioning

confidence: 99%

Long-term cardio-vascular risk assessment in chronic kidney disease and kidney transplanted patients following SARS-COV-2 disease: protocol for multi-center observational match controlled trial

et al. 2022

View full text Add to dashboard Cite

Background The coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a pandemic since March 2020 by affecting more than 243 million people with more than 5 million deaths globally. SARS-CoV-2 infection is produced by binding to angiotensin-converting enzyme, which among other sites is highly expressed in the endothelial cells of the blood vessels, pericytes and the heart, as well as in renal podocytes and proximal tubular epithelial cells. SARS-CoV-2 and cardiovascular disease (CVD) are interconnected by risk factors association with an increased incidence of the disease and by determining de novo cardiac complications. At the same time, COVID-19 disease can lead to acute kidney injury directly, or due to sepsis, multi-organ failure and shock. Therefore, the pre-existence of both CVD and chronic kidney disease (CKD) is linked with a higher risk of severe disease and worse prognosis. Methods The main aim of this study is to assess the CV risk in a CKD (stage 3 to 5), dialysis and kidney transplanted population, following SARS-CoV-2 infection, with focus on the endothelial dysfunction as compared to a control group of matched patients. By using clinical evaluation, flow-mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, lung ultrasound, bioimpedance spectroscopy and a series of novel biomarkers, the investigators will determine the long-term impact of this disease on CV and renal outcomes. Discussion This study will address the challenges and implications in long-term CV sequeale of COVID-19 and focus on a better understanding of the underlying mechanisms and possible therapeutic options. Trial registration Patient enrolment in the trial started in January 2021 and is expected to finish at the end of 2022. The study can be found on ClinicalTrials.gov database with NCT05125913 identifier. Registered on 18 November 2021 - Retrospectively registered.

show abstract

“…Most of the data have been obtained in post-acute COVID-19 or later. Reports of the incidence of cardiac involvement and abnormalities shown with CMR have been heterogeneous among studies [74,75].…”

Section: Cardiac Magnetic Resonancementioning

confidence: 99%

Acute and Chronic Effects of COVID-19 on the Cardiovascular System

Arévalos

Ortega‐Paz

Rodríguez-Arias

et al. 2021

JCDD

View full text Add to dashboard Cite

COVID-19 has shown significant morbidity with the involvement of multiple systems, including the cardiovascular system. Cardiovascular manifestations in the acute phase can include myocardial injury itself, myocardial infarction, venous thromboembolic events, myocarditis, Takotsubo syndrome, and different arrhythmic events. Myocardial injury defined by the rise of cardiac biomarkers in blood has been found in multiple studies with a prevalence of about 20%. Its presence is related to worse clinical outcomes and in-hospital mortality. The mechanisms of myocardial injury have been the subject of intense research but still need to be clarified. The characterization of the cardiac affectation with echocardiography and cardiac magnetic resonance has found mixed results in different studies, with a striking incidence of imaging criteria for myocarditis. Regarding post-acute and chronic follow-up results, the persistence of symptoms and imaging changes in recovered COVID-19 patients has raised concerns about the duration and the possible significance of these findings. Even though the knowledge about this disease has increased incredibly in the last year, many aspects are still unclear and warrant further research.

show abstract

Echocardiography, lung ultrasound, and cardiac magnetic resonance findings in COVID‐19: A systematic review

Cited by 14 publications

References 118 publications

Ultrasound findings of lung ultrasonography in COVID-19: A systematic review

Ultrasound findings of lung ultrasonography in COVID-19: A systematic review

Long-term cardio-vascular risk assessment in chronic kidney disease and kidney transplanted patients following SARS-COV-2 disease: protocol for multi-center observational match controlled trial

Acute and Chronic Effects of COVID-19 on the Cardiovascular System

Contact Info

Product

Resources

About